{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:29:01Z","timestamp":1786768141737,"version":"build-2736575974"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,8,15]]},"DOI":"10.2169\/internalmedicine.6479-25","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T22:08:41Z","timestamp":1767305321000},"page":"2262-2266","source":"Crossref","is-referenced-by-count":0,"title":["VEXAS Syndrome with &lt;i&gt;Vibrio vulnificus&lt;\/i&gt; Sepsis during Treatment with Tocilizumab"],"prefix":"10.2169","volume":"65","author":[{"given":"Eiko","family":"Kawakami","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan"},{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sousuke","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeharu","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagasaki University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniko","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan"},{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Beck DB, Ferrada MA, Sikora KA, et al. Somatic mutations in <i>UBA1<\/i> and severe adult-onset autoinflammatory disease. N Engl J Med 383: 2628-2638, 2020."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Georgin-Lavialle S, Terrier B, Guedon AF, et al.; French VEXAS group; the GFEV, GFM, CEREMAIA, MINHEMON. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol 186: 564-574, 2022.","DOI":"10.1136\/annrheumdis-2022-eular.992"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hadjadj J, Nguyen Y, Mouloudj D, et al. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann Rheum Dis 83: 1358-1367, 2024.","DOI":"10.1136\/annrheumdis-2024-eular.3353"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Beck DB, Bodian DL, Shah V, et al. Estimated prevalence and clinical manifestations of <i>UBA1<\/i> variants associated with VEXAS syndrome in a clinical population. JAMA 329: 318-324, 2023.","DOI":"10.1001\/jama.2022.24836"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Maeda A, Tsuchida N, Uchiyama Y, et al. Efficient detection of somatic <i>UBA1<\/i> variants and clinical scoring system predicting patients with variants in VEXAS syndrome. Rheumatology (Oxford) 63: 2056-2064, 2024.","DOI":"10.1093\/rheumatology\/kead626"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ferrada MA, Savic S, Cardona DO, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood 140: 1496-1506, 2022.","DOI":"10.1182\/blood.2022016985"},{"key":"7","unstructured":"7. de Valence B, Delaune M, Nguyen Y, et al.; French VEXAS Group. Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry. Ann Rheum Dis 83: 372-381, 2024."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Daniels NA. <i>Vibrio vulnificus<\/i> oysters: pearls and perils. Clin Infect Dis 52: 788-792, 2011.","DOI":"10.1093\/cid\/ciq251"},{"key":"9","unstructured":"9. Kamada N. Vibrio vulnificus infections. Nihon Geka Kansensho Gakkai Zasshi (J Jpn Soc Surg Infect) 9: 51-56, 2012."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yun NR, Kim DM. <i>Vibrio vulnificus<\/i> infection: a persistent threat to public health. Korean J Intern Med 33: 1070-1078, 2018.","DOI":"10.3904\/kjim.2018.159"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. El Chaer F, Holtzman NG, Baer MR, Zimrin AB, Law JY. Sickle cell disease complicated by iron overload: an under-recognized risk factor for <i>Vibrio vulnificus<\/i> infection. Acta Haematol 139: 199-200, 2018.","DOI":"10.1159\/000488754"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Brennt CE, Wright AC, Dutta SK, Morris JG Jr. Growth of <i>Vibrio vulnificus<\/i> in serum from alcoholics: association with high transferrin iron saturation. J Infect Dis 164: 1030-1032, 1991.","DOI":"10.1093\/infdis\/164.5.1030"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jones MK, Oliver JD. <i>Vibrio vulnificus<\/i>: disease and pathogenesis. Infect Immun 77: 1723-1733, 2009.","DOI":"10.1128\/IAI.01046-08"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kashimoto T, Ueno S, Hanajima M, et al. <i>Vibrio vulnificus<\/i> induces macrophage apoptosis in vitro and in vivo. Infect Immun 71: 533-535, 2003.","DOI":"10.1128\/IAI.71.1.533-535.2003"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tsuchiya T, Mitsuo E, Hayashi N, et al. <i>Vibrio vulnificus<\/i> damages macrophages during the early phase of infection. Infect Immun 75: 4592-4596, 2007.","DOI":"10.1128\/IAI.00481-07"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chen CL, Chien SC, Leu TH, Harn HI, Tang MJ, Hor LI. <i>Vibrio vulnificus<\/i> MARTX cytotoxin causes inactivation of phagocytosis-related signaling molecules in macrophages. J Biomed Sci 24: 58, 2017.","DOI":"10.1186\/s12929-017-0368-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Choi W, Lee H, Wang Q, Bang YJ, Choi SH. Discovery of a small-molecule inhibitor targeting the biofilm regulator BrpT in <i>Vibrio vulnificus<\/i>. J Microbiol Biotechnol 34: 2201-2210, 2024.","DOI":"10.4014\/jmb.2406.06052"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 116: 3627-3634, 2010.","DOI":"10.1182\/blood-2010-03-271791"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/16\/65_6479-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:11:38Z","timestamp":1786767098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/16\/65_6479-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":18,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6479-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"article-number":"6479-25"}}